(TPST) Tempest Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Tempest Therapeutics, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in one concise framework; it’s designed for marketing research, strategy, and benchmarking. This page includes a real preview/sample of the analysis—purchase the full version to receive the complete ready-to-use report.
Product
Clinical-stage oncology pipeline
Tempest Therapeutics, Inc. is a clinical-stage oncology company, so its core product is a pipeline of experimental small-molecule cancer therapies rather than a marketed drug. The value proposition is tied to advancing these assets through human trials and generating clinical proof of concept, not selling approved products. In 2026, that makes pipeline progress the key product metric, with trial milestones driving most of the company’s product value.
TPST-1495 dual EP2 and EP4 inhibitor
TPST-1495 is Tempest Therapeutics, Inc.’s lead dual EP2 and EP4 inhibitor, designed to block prostaglandin E2 signaling that helps tumors evade immune attack. It is in initial human studies in solid tumors, so the Product story is still early-stage but clinically active. As a lead asset, its value is tied to trial readouts and the company’s ability to move it from first-in-human testing into later oncology development.
TPST-1120 PPAR alpha blocker
TPST-1120 is Tempest Therapeutics, Inc.'s targeted PPAR alpha inhibitor in Phase 1 for solid tumors, built to shift the tumor microenvironment and support immuno-oncology use. Its value in the product mix is clear: it extends Tempest’s pipeline beyond a single asset and fits a biomarker-led cancer strategy. The program matters because Phase 1 assets are still high-risk, but they can drive major pipeline re-rating if early activity is strong.
TREX-1 research focus
Tempest Therapeutics, Inc.’s TREX-1 research is early discovery work, so it adds pipeline depth beyond the lead clinical assets and carries no near-term revenue upside. In FY2025 terms, it fits as a cash-use R&D bet, not a sales driver, but it can create option value if TREX-1 biology proves useful in cancer immunity.
- TREX-1 is preclinical
- Supports pipeline extension
- Not a near-term revenue driver
- Fits FY2025 R&D spend
No approved commercial product
Tempest Therapeutics, Inc. has 0 approved commercial products, so its Product mix is still investigational. Value comes from clinical progress, not pharmacy sales, with pipeline assets moving through trials and regulatory gates.
- No marketed therapy
- Product is trial-based
- Clinical milestones drive value
That means revenue depends on future approvals, not standard drug channel sell-through.
Tempest’s Pipeline Drives Hope as Revenue Stays Zero
Tempest Therapeutics, Inc.’s Product mix is still precommercial: 0 approved drugs, 2 clinical programs, and 1 preclinical asset. In FY2025, value came from trial progress, led by TPST-1495 and TPST-1120, while TREX-1 added early pipeline depth. No product revenue exists yet, so 2026 upside depends on clinical readouts and regulatory steps.
| Metric | FY2025/2026 |
|---|---|
| Approved products | 0 |
| Clinical assets | 2 |
| Preclinical asset | 1 |
| Product revenue | 0 |
What is included in the product
Detailed Word Document
Tempest Therapeutics, Inc. 4P’s analysis breaks down product, pricing, place, and promotion with company-specific context for clear strategic insight.
Editable Excel File
Summarizes Tempest Therapeutics’ 4Ps in a clear snapshot that quickly reveals strategic gaps and opportunities.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and financial filings to speed diligence and validate Tempest Therapeutics' market and financial assumptions.
Place
South San Francisco headquarters
Tempest Therapeutics, Inc. is based in South San Francisco, California, a core biotech cluster next to UCSF and the Bay Area venture market. The headquarters is mainly corporate and scientific, supporting research, strategy, and investor access rather than retail activity. That setting helps Tempest stay close to talent, partners, and lab infrastructure.
Clinical trial sites
Tempest Therapeutics, Inc. uses clinical trial sites as its main "place" channel, because its drugs are still in development and are given only through oncology investigators and study centers. That means access runs through trial networks, not pharmacies or routine hospital sales. In 2025-2026, the business model stays clinical-stage, so site reach and patient enrollment are the key distribution metrics.
Direct sponsor model
Tempest Therapeutics, Inc. runs a direct sponsor model, so it oversees its studies through protocols, investigators, and clinical operations teams. As a clinical-stage company with 0 commercial products, it has no mass-market distribution network yet. That keeps access tightly controlled and tied to trial enrollment, site management, and data capture.
Global investigator network
Tempest Therapeutics, Inc. depends on a global investigator network because solid-tumor studies need many oncology sites to find eligible patients fast. Place is mainly about picking high-accrual cancer centers across key regions so enrollment stays on track and trial costs do not spike from slow recruitment.
- Multi-site oncology reach drives enrollment
- Site choice shapes trial speed and cost
- Global geography supports patient access
No commercial channel yet
Tempest Therapeutics, Inc. has no commercial channel yet: there is no evidence of retail, hospital formulary, or wholesale drug distribution for approved sales. As of 2025, the company remained pre-commercial, with zero product revenue and a place strategy centered on research and clinical development. Market access, payer coverage, and distribution will matter only after regulatory approval.
- No approved sales channel yet
- Pre-commercial and research-led
- Market access starts after approval
Tempest Therapeutics’ 2025-2026 “Place” Is All About Clinical Trial Sites
Tempest Therapeutics, Inc. uses South San Francisco as its operating base, keeping research and investor functions near Bay Area biotech talent. Its Place strategy in 2025-2026 is still clinical-stage, so drug access runs through oncology trial sites, not pharmacies. With zero commercial products and zero product revenue, site choice and patient enrollment remain the key distribution metrics.
| Place factor | 2025-2026 data |
|---|---|
| HQ | South San Francisco, California |
| Commercial products | 0 |
| Product revenue | $0 |
| Channel | Clinical trial sites |
Preview Before You Purchase
Tempest Therapeutics, Inc. Reference Sources
The preview shown here is the actual, full Marketing Mix analysis for Tempest Therapeutics, Inc. you’ll receive instantly after purchase—comprehensive, editable, and ready to use with no surprises.
Promotion
Clinical trial disclosures
Clinical trial disclosures are Tempest Therapeutics, Inc.'s main promotion tool, with ClinicalTrials.gov updates and study announcements reaching investigators, patients, and investors. ClinicalTrials.gov now holds over 500,000 study records, so visibility there matters. For a development-stage biotech with no product sales, each trial update is a direct awareness event and can move sentiment fast.
Press releases
Tempest Therapeutics, Inc. can use press releases to share enrollment, safety, efficacy, and corporate updates from its oncology trials, giving investors and clinicians clear readouts as data mature. This matters in a market where cancer caused about 9.7 million deaths worldwide in 2022, so each update can shape attention fast. Strong releases build credibility around pipeline progress and help keep Tempest visible in capital markets and the oncology community.
Scientific conferences
Scientific conferences are Tempest Therapeutics, Inc.’s main promotion tool because it has no approved product. Oncology meetings like ASCO draw over 40,000 attendees, so poster and oral data let the Company share preclinical and clinical results with researchers and clinicians fast. That helps build visibility, scientific credibility, and trial interest.
Investor relations messaging
Tempest Therapeutics, Inc. uses investor relations promotion to speak to shareholders and financing partners, not just patients. Its updates usually stress mechanism of action, pipeline breadth, and trial milestones, which matters because biotech valuation often moves on clinical data and funding access, not sales.
- Focus: MOA, pipeline, milestones
- Audience: shareholders, financiers
- Driver: data shapes valuation
As a clinical-stage oncology company, Tempest’s message is tied to capital needs and rerating potential.
Medical and scientific communications
Tempest Therapeutics, Inc. uses medical and scientific communications to reach a niche clinical audience, not mass buyers. The message centers on mechanism, biomarkers, safety, and early efficacy, with 2025/2026 focus on data tied to its pre-commercial, oncology pipeline and the goal of building clinician interest and partner trust.
- Targets doctors, KOLs, and partners
- Uses biomarker and safety data
- Drives trial and deal interest
Tempest’s Key Visibility Channels Can Move Sentiment Fast
Tempest Therapeutics, Inc. promotes itself mainly through trial disclosures, press releases, conferences, and investor updates because it has no approved product. ClinicalTrials.gov has over 500,000 study records, and ASCO draws over 40,000 attendees, so these channels give its oncology data reach. In 2025/2026, each safety, efficacy, or enrollment update can move investor sentiment fast.
| Channel | Data point |
|---|---|
| ClinicalTrials.gov | 500,000+ records |
| ASCO | 40,000+ attendees |
Price
No marketed product price
Tempest Therapeutics, Inc. has no approved commercial therapy, so there is no list price or payer-reimbursed price today. Its product revenue is effectively 0 until FDA approval, so pricing only becomes relevant after launch. Any future price will depend on clinical data, label scope, and reimbursement access.
Trial participation funded by sponsor
Tempest Therapeutics, Inc.'s trial "price" is not a retail price: the sponsor funds the investigational drug and trial operations, so patients usually pay $0 for the study drug itself. In this model, value is measured by access and data, not unit sales. That fits a clinical-stage biotech where the end user cost is typically $0 while the sponsor absorbs most trial spend.
Future oncology premium pricing
If approved, Tempest Therapeutics, Inc.'s oncology drug would likely launch at a premium, as targeted cancer therapies often exceed $100,000 per patient per year. Final pricing would hinge on efficacy, safety, patient population size, and payer coverage, with Medicare Part B and commercial reimbursement often shaping net price.
A mechanism-driven pipeline can support value-based pricing if it shows durable response data and a clear survival benefit.
Reimbursement dependent
Tempest Therapeutics, Inc.'s pricing will depend on payer acceptance, prior authorization, and proof of health-economic value, because oncology access is often controlled before a patient starts treatment. In the U.S., 34 million Medicare Advantage members and most commercial plans use utilization management, so reimbursement can decide real uptake more than list price. That makes coverage evidence, not just the sticker price, the key pricing lever.
- Prior auth can slow access.
- Health-economics data supports coverage.
- Reimbursement drives net price.
Capital allocation driven
Tempest Therapeutics, Inc.’s pricing is capital-allocation driven, not product-margin driven. In a clinical-stage biotech, cash use, burn rate, and trial spend decide how much capital Tempest must raise, so pricing logic is really about funding the pipeline and protecting runway.
That makes internal "price" a financing tool: every R and D dollar has to support ongoing studies and keep the company solvent until key data readouts.
- Cash use drives funding needs.
- Burn rate sets runway pressure.
- Trial costs shape capital raises.
Tempest’s $0 Price Today, But Oncology Approval Could Bring Premium Pricing
Tempest Therapeutics, Inc. has no approved drug yet, so its current price is $0 and there is no payer net price. If it wins approval, oncology pricing will likely be premium, often above $100,000 per patient a year, and real uptake will depend on prior auth and coverage. With 34 million Medicare Advantage members, reimbursement can shape net price more than the sticker tag.
| Metric | Price impact |
|---|---|
| Approved therapy | No |
| Current list price | $0 |
| Typical oncology launch | >$100,000/year |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.